MIRM
Mirum Pharmaceuticals, Inc. Common Stock
stockNASDAQ
mirum pharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. its lead product candidate is maralixibat, an investigational oral drug that is in phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of alagille syndrome and biliary atresia disease. the company is also develops volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. mirum pharmaceuticals, inc. was founded in 2018 and is headquartered in foster city, california.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 87.96 | 2026-09-28 | -5.70% | 0.246 |
| 1M | 100.90 | 2026-09-04 | -17.79% | 0.469 |
| 3M | 121.91 | 2026-07-06 | -31.96% | 0.785 |
| 6M | 96.24 | 2026-04-06 | -13.81% | 0.785 |
| 1Y | 72.53 | 2025-10-06 | +14.37% | 0.977 |
| 2Y | 39.26 | 2024-10-04 | +111.28% | — |
| 5Y | 16.73 | 2021-10-05 | +395.82% | 0.732 |
Mirum Pharmaceuticals, Inc. Common Stock (NASDAQ:MIRM) stock price today is $82.95, and today's volume is 1,134,103. MIRM is down 1.156% today. The 30 day average volume is 688,986. MIRM market cap is $5.39B with 64.93M shares outstanding.